Last reviewed · How we verify
NCT03845322: CACTIS
Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence
EARLY_PHASE1 trial testing Curcumin Pill in Hematoma, Subdural, Chronic. Withdrawn.
26 February 2020
Quick facts
| Lead sponsor | University of New Mexico |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Start date | 18 December 2018 |
| Primary completion | 26 February 2020 |
| Estimated completion | 26 February 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Curcumin Pill — full drug profile →
- Placebo pills — full drug profile →
Conditions studied
- Hematoma, Subdural, Chronic — all drugs for Hematoma, Subdural, Chronic →
Sponsor
University of New Mexico
Who can join
18 and older, any sex, with Hematoma, Subdural, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our long-term objective is to evaluate the efficacy of curcumin (CC) in preventing a recurrence of chronic subdural hematoma (cSDH) following surgical evacuation. Recurrence is defined as an increase in total hematoma volume on the operated side compared to a post-operative day one CT scan with persistent or recurrent neurological symptoms. The investigators propose this pilot study to assess feasibility and obtain preliminary benefit assessment of the proposed therapeutic approach. Objective 1: To determine if the use of CC treatment reduces the total hematoma cavity volume over a 6-month interval, compared to a post-subdural drain removal CT scan. This evaluation is expected to offer sufficient evidence for a larger definitive trial. Objective 2: Study the effect of CC on interleukin-8 (IL-8)-induced disruption of endothelial permeability in vitro using human vascular endothelial cells. Central hypothesis: CC treatment prevents the re-accumulation of cSDH, which may occur by inhibition of IL-8 and allowing resolution of the total hematoma cavity volume over six months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03845322
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Curcumin Pill
Trials testing the same drug.
- NCT03144882 — Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients · NA · completed
Other recruiting trials for Hematoma, Subdural, Chronic
Currently open trials in the same condition.
- NCT03582293 — Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma · Phase 3 · recruiting
Other University of New Mexico trials
Trials by the same sponsor.
- NCT07484906 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies · Phase 2 · withdrawn
- NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting
- NCT07265973 — PREPARE: Perioperative REhabilitation Around Vaginal Prolapse RepAir Surgery for Recovery Enhancement · NA · recruiting
- NCT06982443 — Wellness, Alcohol, Vitals, and Emotions · NA · recruiting
- NCT06940609 — Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03845322 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of New Mexico
- Last refreshed: 25 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03845322.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing